Elsevier

Journal of Infection

Volume 68, Issue 1, January 2014, Pages 1-20
Journal of Infection

Review
Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents

https://doi.org/10.1016/j.jinf.2013.08.019Get rights and content

Summary

Objectives

Chronic hepatitis C virus (HCV) infection represents a leading worldwide medical and social problem. The expanding knowledge of HCV lifecycle has led to the development of novel antiviral agents that: a) specifically target a viral function (direct-acting antivirals), or b) specifically inhibit viral replication. The present review describes the novel anti-HCV drugs that have been better studied at the time of this writing and the current two types of treatment, namely interferon-based and interferon-free regimens. In addition, predictive factors, virological responses, side-effects, and resistance mechanisms of the novel agents are summarized.

Conclusions

The introduction of novel antiviral agents is remarkably changing the therapeutic combinations aimed at improving virological responses both for easy-to-cure and difficult-to-treat patients. Since additional, effective drugs are under advanced development, it seems reasonable to expect that further therapeutic and prognostic improvements will be achieved in the near future.

Introduction

Hepatitis C virus (HCV) infection is one of the major causes of chronic liver disease and an important worldwide health problem. It has been calculated that approximately 3% of the global population is chronically infected with HCV, although its prevalence is variable among different geographic areas.1, 2 Six major HCV genotypes (gts) have been identified and their geographic distribution differs, as does their clinical impact with respect to the development of liver disease. HCV gt-1 is the most common genotype worldwide, with a prevalence of subtype 1b in Europe and of subtype 1a in the USA. Intravenous drug users are more frequently infected with gt-3a, especially in Europe. In the Mediterranean area, gt-2 prevails whereas gt-5 and gt-6 are rare.3 Gt-4 is also rare, although its prevalence is relatively high (22%) in the Egyptian population.4

Acute HCV infection is difficult to diagnose because it is usually asymptomatic. While it may resolve spontaneously, in 50–90% of the cases it progresses to chronic infection, with further evolution into cirrhosis in 10–40% of this latter group. Eventually, liver cancer may ensue, with an annual incidence of 1–5% per year.5 These complications are characterized by a high annual mortality rate: roughly 4% of the patients with cirrhosis and 30% of those with hepatocellular carcinoma will die from their disease.6 Thus, all efforts to eradicate the infection are fully justified and require a careful assessment of the many viral factors that promote infection and disease, with the aim of choosing the most appropriate therapeutic regimen. Several recent developments, including the identification of novel predictive factors and improvements in our knowledge of those already established, the adoption of new criteria to define both the duration of therapy and the therapeutic response, as well as the elucidation of resistance mechanisms, have remarkably changed the clinical scenario of HCV infection.

Section snippets

Endpoints of treatment

The combination of pegylated interferon-α (pIFN-α) plus ribavirin (RBV) is the “historical” standard of care for patients with chronic hepatitis C (CHC). The primary goal of antiviral therapy is the achievement of a sustained virological response (SVR), defined as undetectable HCV RNA 24 weeks after the cessation of treatment. In non-cirrhotic patients, SVR is considered curative, whereas those with cirrhosis who have cleared the infection remain at risk of life-threatening complications. The

Potential targets for the development of new anti-HCV agents

The new antiviral agents can be subdivided into two categories: a) DAAs and b) host-targeting antivirals (HTAs). Both DAAs and HTAs target proteins that are essential for viral replication, albeit via different mechanisms (Table 2).

Boceprevir in treatment-naïve patients

SPRINT-2 (Serine Protease Inhibitor Therapy 2)22 was an international, phase III, double-blind, randomized study of HCV gt-1 treatment-naïve patients who received triple PI-based therapy or pIFN-α/RBV plus placebo. Non-Afro-American (n = 938) and Afro-American (n = 159) patients were analyzed separately because of racial differences in SVR rates. pIFN-α2b was administered subcutaneously at a dose of 1.5 μg/kg body weight once weekly; weight-based oral RBV was administered at a total dose of

Combinations of NS3/4A and HCV NS5A inhibitors

A preliminary phase IIa study110 involving patients with HCV gt-1 infection unresponsive to prior therapy showed SVR achievement with only two DAAs. In that study, 21 patients were divided into two groups. Group-1 patients received daclatasvir (60 mg once daily) plus asunaprevir (600 mg twice daily), and group-2 patients daclatasvir plus asunaprevir in combination with pIFN-α/RBV, both for 24 weeks. Almost all group-2 patients had an SVR, in contrast to 36% of the group-1 patients. Diarrhea and

HCV resistance to novel drugs

The RNA-dependent RNA polymerase of HCV is prone to error during the high rate of virion production (up to 1013 particles per day), resulting in the frequent emergence of resistant variants. In the majority of patients, these drug-resistant variants are present before treatment, accounting for minor populations within the quasispecies infecting the patient. Most resistant variants are relatively unfit and undetectable before therapy, even with currently available highly sensitive techniques

Antiviral treatment in HCV-related extrahepatic manifestations

HCV infection is responsible not only for the development of chronic liver disease, but also for the possible occurrence of extrahepatic manifestations. Among them, cryoglobulinemic vasculitis (CV) is of particular interest. This immune-complex-mediated vasculitis primarily involves small blood vessels in different tissues, including skin, kidney, and peripheral and central nervous systems.131, 132 HCV infection has also been reported in association with distinct histological patterns of

Conclusions

While pIFN-α/RBV still remains the SoC for non-gt-1 infections, on the basis of the experience gained with the recently introduced DAAs, the standard of care (SoC) for patients infected with HCV gt-1 is changing and now includes triple therapy with pIFN-α/RBV and either TPV or BOC. The most important studies that have been published so far with both DAAs as summarized in Table 5. However, these new anti-HCV drugs imply high costs and additional adverse events while demanding good compliance

Funding

“Fondazione Cassa di Risparmio di Puglia”, Bari, Italy (DS); Associazione Italiana per la Ricerca sul Cancro – AIRC, Milano, Italy (FD); Italian Ministry of University and Scientific and Technologic Research, National Project “Chronic liver damage induced by hepatitis C virus” (DS); AIFA – Agenzia Italiana del Farmaco, funds for independent studies, 2007, contract no. FARM7SJX (DS); University of Bari, Italy (DS). These funding sources had no role in the present study.

Conflict of interests

All authors declare no competing interests.

References (137)

  • J.G. McHutchison et al.

    Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C

    Gastroenterology

    (2002)
  • A. Balagopal et al.

    IL28B and the control of hepatitis C virus infection

    Gastroenterology

    (2010)
  • C. Sarrazin et al.

    Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients

    J Hepatol

    (2011)
  • C.M. Lange et al.

    Perspectives and challenges of interferon-free therapy for chronic hepatitis C

    J Hepatol

    (2013)
  • R.G. Gish et al.

    The NS5A replication complex inhibitors: difference makers?

    Clin Liver Dis

    (2011)
  • P. Ferenci et al.

    Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy

    Gastroenterology

    (2008)
  • H.H. Gad et al.

    Interferon-lambda is functionally an interferon but structurally related to the interleukin-10 family

    J Biol Chem

    (2009)
  • L. Zhang et al.

    IL28B inhibits hepatitis C virus replication through the JAK-STAT pathway

    J Hepatol

    (2011)
  • T. Marcello et al.

    Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics

    Gastroenterology

    (2006)
  • S. Bruno et al.

    Efficacy and safety of boceprevir plus peginterferon-ribavirin in patients with HCV G1 infection and advanced fibrosis/cirrhosis

    J Hepatol

    (2013)
  • O. Lenz et al.

    TMC 435 in patients infected with HCV genotype 1 who have failed previous pegylated interferon/ribavirin treatment: virologic analysis of the ASPIRE trial

    J Hepatol

    (2012)
  • M.S. Sulkowski et al.

    Sustained viral response and safety of BI201335 combined with peginterferon alfa-2a and ribavirin (P/R) in chronic HCV genotype 1 patients with non-response tp P/R

    J Hepatol

    (2011)
  • A. Suk-Fong Lok

    HCV NS5A inhibitors in development

    Clin Liver Dis

    (2013)
  • S. Pol et al.

    Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial

    Lancet Infect Dis

    (2012)
  • K.M. Hanafiah et al.

    Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to hepatitis C virus seroprevalence

    Hepatology

    (2013)
  • P. Simmonds et al.

    Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes

    Hepatology

    (2005)
  • M.J. Karoney et al.

    Hepatitis C virus (HCV) infection in Africa: a review

    Pan Afr Med J

    (2013)
  • N.H. Afdhal

    The natural history of hepatitis C

    Semin Liver Dis

    (2004)
  • A. Craxì et al.

    EASL Clinical Practice Guidelines: management of hepatitis C virus infection

    J Hepatol

    (2011)
  • H.S. Yee et al.

    Update on the management and treatment of hepatitis C virus infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Office

    Am J Gastroenterol

    (2012)
  • J.G. McHutchison et al.

    Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

    N Engl J Med

    (1998)
  • M.W. Fried et al.

    Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

    N Engl J Med

    (2002)
  • S.J. Hadziyannis et al.

    Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

    Ann Intern Med

    (2004)
  • A. Mangia et al.

    Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3

    N Engl J Med

    (2005)
  • M. Diago et al.

    Identifying hepatitis C virus genotype 2/3 patients who can receive a 16-week abbreviated course of peginterferon alfa-2a (40 KD) plus ribavirin

    Hepatology

    (2010)
  • L.H. Katz et al.

    Extended peginterferon plus ribavirin treatment for 72 weeks versus standard peginterferon plus ribavirin treatment for 48 weeks in chronic hepatitis C genotype 1 infected slow-responder adult patients

    Cochrane Database Syst Rev

    (2012)
  • T. Poynard et al.

    Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest)

    BMC Gastroenterol

    (2010)
  • D.T. Dieterich et al.

    Management of chronic hepatitis C patients who have relapsed or not responded to pegylated interferon alfa plus ribavirin

    J Viral Hepat

    (2009)
  • L. Roffi et al.

    Pegylated interferon-alpha2b plus ribavirin: an efficacious and well-tolerated treatment regimen for patients with hepatitis C virus related histologically proven cirrhosis

    Antivir Ther

    (2008)
  • F. Poordad et al.

    Boceprevir for untreated chronic HCV genotype 1 infection

    N Engl J Med

    (2011)
  • I.M. Jacobson et al.

    Telaprevir for previously untreated chronic hepatitis C virus infection

    N Engl J Med

    (2011)
  • K.E. Sherman et al.

    Response-guided telaprevir combination treatment for hepatitis C virus infection

    N Engl J Med

    (2011)
  • B.R. Bacon et al.

    Boceprevir for previously treated chronic HCV genotype 1 infection

    N Engl J Med

    (2011)
  • S. Zeuzem et al.

    Telaprevir for retreatment of HCV infection

    N Engl J Med

    (2011)
  • G.L. Davis et al.

    Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression

    Gastroenterology

    (2010)
  • D. Ge et al.

    Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

    Nature

    (2009)
  • Y. Tanaka et al.

    Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C

    Nat Genet

    (2009)
  • V. Suppiah et al.

    IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy

    Nat Genet

    (2009)
  • A. Rauch et al.

    Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study

    Gastroenterology

    (2010)
  • N. Ank et al.

    An important role for type III interferon (IFN-lambda/IL-28) in TLR-induced antiviral activity

    J Immunol

    (2008)
  • Cited by (0)

    View full text